Tarsus Pharmaceuticals (TARS) Cash & Equivalents (2019 - 2026)

Tarsus Pharmaceuticals' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $102.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 41.87% year-over-year to $102.2 million; the TTM figure through Mar 2026 stood at $102.2 million (down 41.87% YoY), while the FY2025 annual figure was $183.6 million, up 93.68% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $102.2 million, down from $183.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $245.4 million in Q2 2022, with the low at $66.0 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $175.0 million (2022), against an average of $153.1 million.
• Peak annual rise in Cash & Equivalents reached 213.91% in 2023, while the deepest fall reached 62.29% in 2023.
• Tarsus Pharmaceuticals' Cash & Equivalents stood at $71.7 million in 2022, then soared by 213.91% to $224.9 million in 2023, then plunged by 57.85% to $94.8 million in 2024, then jumped by 93.68% to $183.6 million in 2025, then sank by 44.35% to $102.2 million in 2026.
• Business Quant data shows TARS's Cash & Equivalents at $102.2 million in Q1 2026, $183.6 million in Q4 2025, and $112.7 million in Q3 2025.